Micromet AG and MedImmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia. © The Thomson Corporation.
|Number of pages||6|
|Journal||Current Opinion in Molecular Therapeutics|
|Publication status||Published - Feb 2006|